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Abstract
While nullizygous loss of NF1 leads to myeloid malignancies, haploinsufficient loss of NF1 (Nf1) 
has been shown to contribute to osteopenia and osteoporosis which occurs in approximately 50 
percent of neurofibromatosis type 1 (NF1) patients. Bone marrow mononuclear cells of 
haploinsufficient NF1 patients and Nf1+/- mice exhibit increased osteoclastogenesis and 
accelerated bone turnover, however the culprit hematopoietic lineages responsible for perpetuating 
these osteolytic manifestations have yet to be elucidated. Here we demonstrate that conditional 
inactivation of a single Nf1 allele within the myeloid progenitor cell population (Nf1-LysM) is 
necessary and sufficient to promote multiple osteoclast gain-in-functions, resulting in enhanced 
osteoclastogenesis and accelerated osteoclast bone lytic activity in response to pro-resorptive 
challenge in vivo. Surprisingly, mice conditionally Nf1 heterozygous in mature, terminally 
differentiated osteoclasts (Nf1-Ctsk) do not exhibit any of these skeletal phenotypes, indicating a 
critical requirement for Nf1 haploinsufficiency at a more primitive/progenitor stage of myeloid 
development in perpetuating osteolytic activity. We further identified p21Ras dependent hyper-
phosphorylation of Pu.1 within the nucleus of Nf1 haploinsufficent myelomoncytic osteoclast 
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precursors, providing a novel therapeutic target for the potential treatment of NF1 associated 
osteolytic manifestations.
Introduction
Myelomonocytic precursor cells give rise to multinucleated, bone resorptive osteoclasts 
(OCs)(1). The physiologic lineage commitment of monocyte-macrophage precursor cells is 
pivotal to maintain skeletal homeostasis. Deregulated OC differentiation, recruitment, and/or 
function can result in either osteoporosis or osteopetrosis(2,3), affecting not only the skeleton 
but altering the bone marrow niche as well(4-6). The cytokines macrophage-colony 
stimulating factor (M-CSF)(7) and receptor activator of nuclear factor κB ligand 
(RANKL)(8,9) are indispensable for macrophage and OC development, respectively. Op/op 
mice lacking M-CSF exhibit severe osteopetrosis due to an absence of both OCs and 
macrophages. Adoptive transfer of wild-type (WT) hematopoietic cells is insufficient to 
correct osteopetrotic phenotypes in op/op recipient mice(10), suggesting that the failure of 
macrophage and OC differentiation in op/op mice is contingent on the extrinsic absence of 
M-CSF as opposed to intrinsic deficits in either the M-CSF receptor (c-Fms) or intracellular 
signaling effectors. By contrast, hypersensitivity of macrophages to M-CSF and RANKL in 
SHIP deficient mice has been shown to result in osteoporosis(11).
Mutations in the NF1 tumor suppressor gene lead to malignant and non-malignant disease 
manifestations of neurofibromatosis type I (NF1), including cutaneous and plexiform 
neurofibromas, optic nerve gliomas, malignant peripheral nerve sheath tumors (MPNSTs), 
juvenile myelomoncytic leukemia (JMML), cognitive impairment, cardiovascular disease, 
and skeletal defects(12). Neurofibromin, the protein encoded by NF1, functions as a GTPase-
activation protein (GAP) for Ras, negatively regulating its functional activity(13). 
Experimental data now indicates that Nf1 gene dose (Nf1 haploinsufficiency) in 
hematopoietic derived cells plays a pivotal role in multiple NF1 associated phenotypes 
including plexiform neurofibromas, neointima formation, and skeletal anomalies osteopenia 
and osteoporosis(14).
Clinical studies demonstrate that approximately 50 percent of the NF1 patient population 
suffers from osteopenia or osteoporosis(15-20), resulting in significantly increased rates of 
long-bone fracture(20,21). Mononuclear cells cultured from the peripheral blood of NF1 
patients and the bone marrow of Nf1+/- mice exhibit increased OC differentiation and bone 
resorptive capacity in vitro(22-24). However, the functional requirement for Nf1 
haploinsufficiency in perpetuating these osteolytic manifestations has yet to be elucidated in 
a step-wise and lineage restricted fashion within the hematopoietic compartment. Although 
Nf1+/- myelomonocytic OC progenitor cells exhibit intrinsic, p21-Ras and PI3K dependent 
hypersensitivity to M-CSF and RANK-L(22), the putative contribution of extrinsic alterations 
in cytokine levels within the Nf1 deficient bone microenvironment is difficult to segregate as 
a confounding factor. For instance, hypersecretion of osteopontin (OPN)(25), transforming 
growth factor-beta1 (TGF-β1)(26) and RANKL(27) by Nf1 null osteoprogenitor cells, 
together with the decreased expression of the RANKL decoy receptor, osteoprotegerin 
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(OPG)(27), have each been implicated as potential paracrine factors perpetuating osteolytic 
activity in murine models of the disease.
To understand the cell autonomous and step-wise role of Nf1 gene dose in regulating 
myeloid lineage commitment and OC differentiation, we generated Nf1-LysM and Nf1-Ctsk 
mice harboring conditional inactivation of a single Nf1 allele in myeloid progenitor cells(28) 
and mature OCs(29), respectively. Here we demonstrate that haploinsufficient loss of Nf1 
within myeloid progenitor cells is necessary and sufficient to perpetuate multiple OC gain-
in-functions both in vitro and in vivo, reminiscent of the phenotype of Nf1+/- mice(22). We 
further delineate a mechanism by which p21-Ras hyperactivation results in accumulation of 
phosphorylated Pu.1 within the nucleus of myelomoncytic osteoclast precursors, which may 
be associated with enhanced osteoclastogenesis, and provide a novel therapeutic target for 
the potential treatment of NF1 associated osteolytic manifestations.
Methods
Animals
Nf1-floxed (Nf1flox/flox) mice were generated in the laboratory of Dr. Luis Parada 
(University of Texas Southwestern Medical Center) as described previously(30). LysMCre 
mice, generated by Dr. Irmgard Forster (University of Duesseldorf)(28), and CtskCre mice, 
generated by Dr. R.A. Davey (University of Malbourne, Australia)(29) were obtained from 
the Jackson Laboratory. Breeding of Nf1flox/flox mice with LysMCre and CtskCre mice 
yielded LysMCre;Nf1flox/+ and CtskCre;Nf1flox/+ mice (abbreviated respectively as Nf1-
LysM and Nf1-Ctsk throughout this manuscript) which were maintained at the Indiana 
University School of Medicine in accordance with the Institutional Animal Care and Use 
Committee and Institutional Review Board guidelines. Cre mediated recombination of the 
floxed Nf1 allele was validated by PCR and western blot (Supplemental Figure 1A-C). The 
genotype of wild-type (WT) mice were either Nf1flox/flox;Cre(-) or Nf1flox/+;Cre(-) for each 
colony. For all experiments, WT mice were obtained from the same colony as the 
corresponding mutant mice.
Bone marrow isolation
Bone marrow was flushed from the femur, tibia, and iliac crest in a 5 mL volume of Iscove's 
Modified Dulbecco's Media (IMDM, Gibco/Invitrogen), supplemented with 1% fetal bovine 
serum (FBS, Hyclone, ThermoScientific) using a 1.5 inch 23-guage needle. Low density 
bone marrow mononuclear cells (BMMNCs) were isolated by density gradient 
centrifugation for 30 minutes at 1750 rpm (gh-3.8 rotor, Beckman Coulter) on a 3.5 mL 
volume of Histopaque (Sigma). The buffy coat layer was collected and washed with IMDM 
or other media prior to further assays.
Colonogenic progenitor assays
To determine the frequency of myeloid progenitors in bone marrow, colony-forming unit-
macrophage/monocyte (CFU-M) of BMMNCs were performed by seeding 2.5 × 104 
BMMNCs into 35-mm gridded dishes containing methylcellulose supplemented with 
varying doses of murine recombinant M-CSF (0.1, 1, 10, and 50 ng/mL) for 7 days at 37°C 
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in a 5% CO2 incubator(22). Colony type and numbers were counted on an inverted light 
microscope.
Osteoclast differentiation
Murine osteoclasts were cultured in vitro from mouse BMMNCs as described previously(22) 
using α-MEM medium supplemented with 10% FBS in the presence of murine recombinant 
macrophage-colony stimulating factor (M-CSF, 30 ng/mL) and murine recombinant receptor 
activator of nuclear factor kappa-B ligand (RANKL, 20 ng/mL). On day three of culture, the 
cytokines were changed to M-CSF (30 ng/mL) and RANKL (60 ng/mL) for an additional 
three days of culture. Adherent cells were then fixed and stained for tartrate resistant acid 
phosphatase (TRACP) according to the manufacturer's instructions (Sigma-Aldrich, USA). 
TRACP-positive staining osteoclast cells were visualized and photographed with a Nikon 
TE2000-S microscope (Nikon Inc., Melville, NY) equipped with a QImaging camera (Fryer 
Company Inc., Cincinnati, OH). Mature osteoclasts were defined as multinucleated TRACP-
positive staining cells containing greater than or equal to three nuclei. Osteoclast nuclear 
number and area were scored using NIH Image J Software.
Bone resorption assays
BMMNCs were seeded on dentine slices (ALPCO Diagnostic, Windham, NH) and cultured 
in the presence of M-CSF and RANK-L at 37°C, 5% CO2 for 7 days. The area of resorptive 
“pits” was quantified on low power fields using NIH Image J Software.
Flow cytometry
BMMNCs were incubated for 45 minutes at 4°C with saturating concentrations of anti-
mouse antibodies in ∼100 μL 3% FBS/0.09% NaN3 in PBS with 0.25 μg anti-mouse CD16/
CD32 (“Fc Block”). For the myeloid progenitor analysis, the following antibodies from BD 
Biosciences were used: FITC-conjugated anti-lineage markers (CD3, CD4, CD8, B220, 
Mac1, Gr1, Ter119), anti-CD16/32-PE, anti-CD34-PacificBlue, anti-Sca1-APC-Cy7, and 
anti-c-Kit-PerCP-Cy5.5. For the mature lineage analysis, the following antibodies from BD 
Biosciences were used: anti-CD3-FITC, anti-CD8-PacBlue, anti-B220-V500, anti-Mac1-PE, 
anti-Gr1-PECy7, anti-CD4-APC-Cy7, anti-CD45.2-PerCP-Cy5.5. Cells were analyzed on an 
LSR II 407 flow cytometer, and single color compensation controls were acquired using 
polystyrene microbeads (BD Biosciences). All post-acquisition analyses were performed 
with FlowJo 7.6.3 software (TreeStar, WA) with gating parameters determined by 
fluorescence minus-one controls.
The following gating definitions were used: MPs, myeloid progenitors; GMPs, granulocyte-
monocyte progenitors; MEPs, megakaryocyte-erythroid progenitors. MPPs: Lin–Sca1+c-
Kit+; MPs: Lin–Sca1–c-Kit+. CMPs: Lin–Sca1–c-Kit+CD34+FcγRII/II–/lo. GMPs: 
Lin–Sca1–c-Kit+CD34+FcγRII/ II+. MEPs: Lin–Sca1–c-Kit+CD34–FcγRII/II–. HSPCs: 
CD150+Lin–CD48–CD41–Sca1+c-Kit+. Myeloid cells: CD3–B220–; Monos: 
CD3–B220–Gr1–Mac1+.
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Pro-resorptive challenge
12-week old, female WT, Nf1-LysMCre, and Nf1-CtskCre mice underwent either 
ovariectomy or sham surgery(22). Briefly, mice were anesthetized using a mixture of 
ketamine (150 mg/kg) and xylazine (10 mg/kg) administered by intraperitoneal (IP) 
injection. A 2-cm midline dorsal skin incision was performed, followed by incision of the 
peritoneal cavity to identify and excise the ovaries. Bone mineral density (BMD) was 
measured once prior to surgery and again after 6 weeks to track the percent change in BMD 
over time. The mice were subsequently euthanized and the long bones were dissected for 
further analysis by micro-computed tomography (μCT) and histological methods described 
below. The cohort sizes of the experimental (OVX) and sham operated control groups were 
chosen to achieve sufficient statistical power to detect a significant difference in bone 
mineral density between genotypes within treatment groups six weeks status-post surgery, 
according to our previously published work(22).
Peripheral dual-energy X-ray absorptiometry (pDEXA)
Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DEXA) 
with a Lunar Piximus densitometer (GE Lunar II, Faxitron Corp., Wheeling, IL)(22). Mice 
were anesthetized with a mixture of ketamine (150 mg/kg) and xylazine (10 mg/kg) injected 
IP. Animals were scanned in the prone position with arms and legs extended. A region of 
interest was defined as the distal femur adjacent to the growth plate (12 × 12 pixels). For 
ovariectomy experiments, the percent change in BMD was determined by comparing the 
initial measurement with an endpoint scan, acquired 6 weeks following OVX or sham 
surgery.
Micro-computed tomography (μCT)
Formalin fixed femora were placed in the gantry of a VivaCT 40 micro-computed 
tomographer (Scanco Medical AG, Bassersdorf, Switzerland). Images were acquired at 55 
kV and 145 mA with a voxel size of 10.5 μm. A region of interest was defined as 100 
transverse CT slices beginning 250 μm away from the growth plate and extending 
proximally. Fractional bone volume (BV/TV, Fraction) and architectural properties of 
trabecular reconstructions: trabecular thickness (Tb.Th, μm), trabecular number (Tb.N, 
mm-1), trabecular spacing (Tb.Sp, 1/mm), and connectivity density (Conn.D., mm-3) were 
calculated as described previously(31). For quantitative evaluation of tibial fracture calluses, 
contouring was performed for 100 transverse CT slices extending in both directions from the 
fracture midline. Callus fractional bone volume (BV/TV) and volumetric bone mineral 
density (vBMD) were measured within the callus, excluding the cortical bone comprising 
the original tibial shaft.
Quantitative histomorphometry
Tissues were fixed in 10% formalin for 48 hours, demineralized for 2 weeks in 10% EDTA, 
and embedded in paraffin. 3.5 μm thick longitudinal sections were cut using a rotary 
microtome (Leica). Trabecular bone volume fraction (BV/TV) of the secondary spongiosa 
and osteoblast number (N.Ob/BS) normalized to the bone surface were quantified on H&E 
stained sections of the distal femur at 200× magnification using BIOQUANT OSTEO v11.2 
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software (BIOQUANT Image Analysis Inc., Nashville, TN). In a similar fashion, osteoclast 
number normalized to the bone surface (N.Oc/BS) was quantified on tartrate resistant acid 
phosphatase (TRACP) stained sections at 200× magnification.
Western blotting
Following stimulation with M-CSF, RANKL, and various inhibitors, nuclear and 
cytoplasmic protein fractions were harvested using a Nuclear/Cytosol Fractionation kit 
(Biovision, San Francisco, CA). Isolated proteins were fractionated using NuPAGE 4-12% 
Bis-Tris Gels (Invitrogen) and electro-transferred to PVDF membranes. Immunoblots were 
carried out using antibodies specific to Pu.1 (Abcam) and β-actin (Sigma). After incubation 
with anti-rabbit IgG or anti-mouse IgG (GE Healthcare) antibodies conjugated with HRP, 
signals were detected using ECL chemoluminescence substrate (ECL Prime, GE 
Healthcare). Intensity of bands was determined using Image J software.
Phosphatase treatments
Nuclear protein lysates were isolated from Nf1+/- osteoclast progenitor cells following 12 
hours stimulation with M-CSF (30 ng/mL) and RANKL (30 ng/mL). Potato acid 
phosphatase (Sigma) was reconstituted at a concentration of 0.05 U/μL. Heat activation was 
performed by heating the reconstituted phosphatase to 100°C for 15-20 minutes prior to 
incubation with nuclear protein lysates. Phosphatase treatments were performed by adding 
0.05 U of either active or heat inactivated phosphatase to nuclear protein lysates, which were 
incubated at 37°C for a duration of 30 minutes. SDS was subsequently added to each 
sample, followed by heating to 100°C for 10 minutes to quench to reaction prior to western 
blotting.
Statistical analysis
Differences between experimental groups were interrogated using the Student's t-test or 
either one- or two-factor analysis of variance (ANOVA) statistical tests as appropriate. In the 
instances where the ANOVA was significant, post-hoc testing was performed between 
individual groups using the Newman-Keuls multiple comparison test. An alpha level of 5% 
was set as the type I error rate for all studies, with p values < 0.05 required to reject the null-
hypothesis.
Results
Conditional Nf1 haploinsuffiency in myeloid progenitor cells promotes expansion of the 
OC precursor pool, enhancing OC maturation and bone lytic activity
Osteoclastogenesis is a dynamic process requiring the commitment and proliferation of early 
myeloid progenitors, followed by terminal myelomonocytic differentiation, and ultimately 
fusion to multinucleated OCs with bone resorptive activity(1). Mononuclear cells harvested 
from the bone marrow of Nf1+/- mice and peripheral blood of human NF1 patients exhibit an 
increased propensity for OC differentiation and bone resorption ex vivo due to p21-Ras 
mediated hypersensitivity to M-CSF and RANK-L(22-24). Yet no genetic study has directly 
assessed the stage of myeloid or OC differentiation at which Nf1 haploinsufficiency is 
permissive of these gain-in-functions. To investigate the temporal role of Nf1 gene dose in 
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regulating early versus late stage osteoclast development, we began by comparing myeloid 
lineage commitment and proliferative capacity of BMMNCs harvested from Nf1-LysM, 
Nf1-Ctsk, and wild-type (WT) mice. When BMMNCs isolated from these mice were 
cultured in semisolid methycellulose media supplemented with varying concentrations of M-
CSF, we found that the number of colony forming unit-macrophage (CFU-M) per femur 
were significantly increased in Nf1-LysM BMMNCs versus WT with increasing doses of M-
CSF (Figure 1A). In a complementary approach, flow cytometric analysis of the bone 
marrow revealed a significant increase in the frequency of myeloid progenitors (Figure 1B). 
Thus, conditional Nf1 haploinsufficiency in early stage myeloid progenitor cells is sufficient 
to promote expansion of the OC precursor pool as previously observed in Nf1+/- mice(22). 
By contrast, however, when we compared the frequency of CFU-M generated from Nf1-
Ctsk BMMNCs in M-CSF supplemented methycellulose culture, we observed no significant 
difference as compared to the WT control (Supplemental Figure 2A), indicating that 
conditional Nf1 haploinsufficiency restricted to the terminal stages of OC differentiation 
does not alter the lineage commitment or frequency of more primitive myeloid progenitor 
cells.
We next sought to assess the capacity of Nf1-LysM, Nf1-Ctsk, and WT BMMNCs to 
undergo terminal OC differentiation in response to M-CSF and RANK-L. Given the 
increased frequency of myelomonocytic OC progenitor cells within the bone marrow of 
Nf1-LysM mice, we hypothesized that BMMNCs harvested from these animals would 
concordantly exhibit enhanced osteoclastogensis. Indeed, the number of tartrate resistant 
acid phosphatase (TRACP) positive staining multinucleated OCs (Figure 1C), number of 
nuclei per osteoclast, and mean osteoclast size (Figure 1D) were significantly increased in 
Nf1-LysM BMMNC cultures as compared to WT controls suggesting increased osteoclast 
progenitor fusion and recapitulating the hallmark features of osteoclasts cultures derived 
from the bone marrow of Nf1+/- mice (22) and the peripheral blood of human NF1 
patients(23,24). Although Nf1-Ctsk mice do not exhibit any apparent increase in the 
frequency of OC progenitors within the bone marrow, we nonetheless reasoned that Nf1 
haploinsufficiency, even restricted to late stage osteoclastogenesis, might still be sufficient to 
potentiate osteoclast maturation. As expected, we observed no significant difference in the 
osteoclastogenic capacity of Nf1-Ctsk BMMNCs as compared to WT cultures 
(Supplemental Figure 2B), suggesting that Nf1 haploinsufficiency in the terminal stages of 
OC development alone is insufficient to potentiate osteoclast differentiation as compared to 
genetic disruption of a single Nf1 allele in more primitive myeloid progenitor cells. These 
data also serve as a negative control to exclude the putative contribution of paracrine factors 
from Nf1 heterozygous mature osteoclasts that could act on immature cells of the myeloid 
lineage to promote terminal differentiation.
A defining morphological feature of mature osteoclasts is the organization of the actin 
cytoskeleton to form a specialized cell–extracellular matrix that provides the appropriate 
microenvironment for bone matrix degradation. This complex structure is formed by the 
coalescence of actin cytoskeletal structures termed podosomes that arrange into identifiable 
patterns such as clusters, rings and ultimately belts that constitute a functional sealing 
zone(32). Here, we show that compared to WT controls, Nf1-LysM osteoclast cultures 
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exhibit significantly higher levels of belt formation (Figure 1E,F), another characteristic 
cellular feature observed in Nf1+/- osteoclasts with increased bone resorptive activity(33).
To directly assess the functional capacity of OCs to degrade bone matrix, OCs were cultured 
on dentine slices in the presence of M-CSF and RANK-L to quantify the area of “pits” 
generated by osteoclast mediated erosion. Consistent with previous data demonstrating 
increased bone resorptive capacity of OCs cultured from the Nf1+/- mice(22), we observed a 
significant increase in “pit” area on dentine slices seeded with Nf1-LysM OCs as compared 
to WT controls (Figure 1G). Consistent with previous negative findings, Nf1-Ctsk OC 
cultures did not exhibit a significant difference in “pit” resorptive capacity as compared to 
WT (Supplemental Figure 2C).
Nf1 haploinsufficiency in myeloid progenitor cells is necessary and sufficient to 
accentuate osteolytic activity in vivo
Intriguingly, although Nf1+/- OCs exhibit multiple gain-in-functions(22), Nf1+/- mice do not 
spontaneously exhibit commensurate reductions in bone mass or quality as compared to WT 
mice(34). By contrast, we previously demonstrated that the consequences of Nf1 
haploinsufficiency can be unmasked in vivo following ovariectomy (OVX) induced pro-
resorptive challenge, whereby Nf1+/- mice lose bone mass at approximately double the rate 
of WT littermates perpetuated by excess osteolytic activity(22). To characterize the 
functional consequences of cell-autonomous Nf1 haploinsufficiency in myeloid progenitor 
cells versus terminally differentiated osteoclasts in response to pro-resorptive stress, we 
ovariectomized Nf1-LysM and Nf1-Ctsk mice and monitored changes in their bone mass 
and bone mineral density as compared to WT controls.
Consistent with previous findings, we observed no significant baseline differences in bone 
mineral density, bone mass, or trabecular architecture between either Nf1-LysM 
(Supplemental Figure 3A, B) or Nf1-Ctsk mice (Supplemental Figure 4A, B) versus WT 
controls. However, following OVX induced pro-resorptive challenge, the rate of bone loss 
was significantly increased in Nf1-LysM-OVX mice as compared to WT controls. Nf1-
LysM-OVX mice exhibited a 10.8 ± 1.5 (SEM) percent reduction in distal femoral bone 
mineral density (BMD) during the 6 weeks following OVX surgery versus WT animals 
which lost only 6.8 ± 0.7 (SEM) percent of distal femoral BMD (Figure 2B). As an 
additional control group, sham-operated animals gained approximately 1-3% of femoral 
BMD over the 6-week time course. Representative micro-computed tomography (μCT) 
reconstructions illustrate the marked loss of trabecular bone in OVX Nf1-LysM mice as 
compared to OVX WT controls (Figure 2A). Corroborating these data, quantitative μCT 
evaluation revealed significant deficits in femoral bone volume fraction (BV/TV) (Figure 
2C), with commensurate changes in multiple bone microarchitecture parameters, including 
trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular spacing (Tb.Sp) 
between OVX Nf1-LysM and OVX WT mice (Figure 2D-F, respectively). Finally, 
histomorphometric enumeration of TRACP positive multinucleated OCs lining the 
trabecular bone surface revealed significantly increased osteoclast numbers in the femora of 
OVX Nf1-LysM mice (Figure 2G,H), implicating enhanced osteoclastogenesis as the pivotal 
factor promoting excess bone catabolic activity in Nf1-LysM animals.
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Intriguingly, when analogous studies were performed in Nf1-Ctsk mice, whereby Nf1 
haploinsufficiency is restricted to mature, terminally differentiated OCs, we observed no 
significant differences in bone mass or microarchitecture parameters when comparing WT- 
and Nf1-Ctsk-OVX mice. Although bone loss occurred in both the mutant and control 
animals, the percentage reduction in femoral BMD was equivalent between WT- and Nf1-
Ctsk-OVX mice (Figure 3A). Representative μCT reconstructions illustrate comparable bone 
loss in the distal femur between ovariectomized WT and Nf1-Ctsk mice (Figure 3B). 
Quantitatively, we detected no significant difference in femoral BV/TV (Figure 3C) or 
trabecular architecture parameters (Figure 3D-I.) when comparing Nf1-Ctsk and WT 
animals following OVX. Collectively, these data imply that conditional Nf1 
haploinsufficiency in mature OCs is insufficient to perpetuate increased osteolytic lytic 
activity in response pro-resporptive challenge; but rather, genetic ablation of Nf1 in more 
primitive myeloid progenitor cells appears to be required to permit expansion of the OC 
precursor pool within the bone marrow, thereby promoting accelerated bone resorption in 
vivo.
Previous studies have demonstrated the LysM-Cre driver to be relatively specific to primitive 
myeloid lineages within the hematopoietic compartment(28). Nonetheless, to further confirm 
that the observed phenotype in Nf1-LysM mice was unrelated to possible ectopic 
recombination or “leakage” of the LysM-Cre driver in the osteoblast lineage, osteoblasts 
were enumerated on the bone surface in WT and Nf1-LysM mice (Supplemental Figure 3C). 
We observed no significant difference in the number of osteoblasts per mm bone surface 
(Ob.N/BS, mm-1) within the distal femur when comparing Nf1-LysM mice to the WT 
control, suggesting that the enhanced bone loss in Nf1-LysM mice in response to pro-
resorptive stress is primarily related to increased osteoclast bone lytic activity.
Nf1 haploinsufficiency in OC progenitors results in Ras-dependent accumulation of 
phosphorylated Pu.1 in the nucleus
Given that haploinsufficient loss of Nf1 in myeloid progenitor cells is critical to promoting 
increased osteolytic activity in vivo, we therefore reasoned that neurofibromin may play a 
pivotal role in regulating the expression and/or activity level of myeloid dependent 
transcription factors. Pu.1 transcriptional activity is required for myelomonocytic and 
osteoclast differentiation, whereby mice lacking Pu.1 exhibit severe osteopetrosis and are 
deficient in both macrophages and OCs secondary to impaired expression of the M-CSF 
receptor, c-Fms(35). Here, we show that the expression level of Pu.1 is increased in the 
nucleus of Nf1 haploinsufficient OC progenitors relative to WT controls stained with FITC-
labeled anti-Pu.1 (green) and Hoescht (blue) (Figure 4A). We next performed western blot 
analysis to examine Pu.1 protein levels in OC progenitors treated with M-CSF and RANK-
L. When we probed with Pu.1-specific antiserum (Santa Cruz, CA), the predominant protein 
detected in WT nuclear lysates migrated at an apparent molecular weight of approximately 
35 kD. Intriguingly, the expression of two additional bands in the 40-55 kD range was 
markedly enriched in the Nf1+/- nuclear lysates across multiple timepoints (Figure 4B).
Phosphorylation of Pu.1 is known to retard its migration in SDS-PAGE 
electrophoresis(36,37). To confirm that these band shifts represent phosphorylated forms of 
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Pu.1, nuclear lysates were treated with potato acid phosphatase prior to electrophoresis. 
Phosphatase treatment resulted in complete conversion of the shifted bands to the lower 
molecular weight, unphosphorylated Pu.1 species (Figure 4C). By contrast, treatment of the 
lysates with heat denatured potato acid phosphatase did not alter the migration or intensity 
of the shifted bands, thus validating that these bands correspond specifically to 
phosphorylated Pu.1 species (Figure 4C).
Given neurofibromin's function as a GTPase activating protein (GAP) for p21-Ras, we 
therefore reasoned that p21-Ras hyperactivation in Nf1 haploinsufficent osteoclasts may 
underlie the accumulation of the phosphorylation form of Pu.1 in the nucleus. To test this 
hypothesis, we transduced primary Nf1+/- c-kit+ hematopoietic cells with a recombinant 
retrovirus encoding the full length NF1 GAP-related domain (GRD) and a selectable marker, 
pac, which confers resistance to puromycin(38). As compared to Nf1+/- c-kit+ cells 
expressing MSCV-pac alone, reconstitution of the full length NF1-GRD in Nf1 
haploinsufficient c-kit+ cells significantly attenuated the phosphorylation of nuclear Pu.1 
(Figure 4D). Given recent findings implicating Pu.1 phosphorylation in the transcriptional 
activation of terminal myeloid specific gene programs(39,40), we postulate this to be a 
previously unrecognized mechanism by which Nf1 haploinsufficiency engenders myeloid 
lineage commitment, thereby promoting osteoclastogenesis and hyper-resorptive activity.
Discussion
OCs cultured ex vivo from the bone marrow of Nf1+/- mice and the peripheral blood of 
human NF1 patients exhibit multiple gain-in-functions(22-24), consistent with clinical 
observations that NF1 patients have reduced bone mineral density(15-19,41) and are 
predisposed to increased fracture risk(20,21). However, the functional requirement for Nf1 
haploinsufficiency within hematopoietic cells to perpetuate these osteolytic manifestations 
has yet to be elucidated in a step-wise, lineage restricted fashion. Here we demonstrate that 
conditional inactivation of a single Nf1 allele within the myeloid progenitor cell population 
(Nf1-LysM) is necessary and sufficient to promote multiple osteoclast gain-in-functions, 
resulting in increased osteoclast progenitor fusion, enhanced osteoclastogenesis, and 
accelerated osteoclast bone lytic activity in response to pro-resorptive challenge in vivo. 
Intriguingly, mice conditionally Nf1 heterozygous in mature, terminally differentiated 
osteoclasts (Nf1-Ctsk) do not recapitulate these phenotypes, indicating a critical requirement 
for Nf1 haploinsufficiency at a more primitive stage of myeloid development in perpetuating 
enhanced osteolytic activity. Given that genetic ablation of a single Nf1 allele in terminally 
differentiated osteoclasts alone is insufficient to augment the rate of bone lytic activity, we 
thus postulate that expansion of the osteoclast precursor pool and an overall increase in 
osteoclast numbers are the preponderant factors driving bone resorption in the context of 
Nf1 haploinsufficiency (Figure 5).
In contrast to the Nf1-Ctsk model which does not display evidence of osteoclast 
hyperactivity as observed in Nf1-LysM and Nf1+/- animals(22), Alanne and colleagues 
recently reported that transgenic mice harboring conditional Nf1 nullizygous (Nf1-/-) 
osteoclasts driven by TRAPCre, exhibit increased bone resorptive capacity and aberrant 
actin ring formation in vitro(42). Despite differences in Nf1 gene dose (Nf1 heterozygosity in 
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Nf1-Ctsk mice versus biallelic Nf1 inactivation in the TRACPCre;Nf1flox/flox model), we 
postulate that the apparent osteoclast gain-in-functions in this mouse model are likely due to 
the expression of TRAPCre in more primitive stages of osteoclast/myeloid development as 
compared to CtskCre, which is restricted to mature, terminally differentiated osteoclasts(29). 
Supporting this concept, the authors report that TRACPCre;Nf1flox/flox mice exhibit a 
number of extra-osseous features including splenomegaly and megakaryocytosis(42). These 
findings are reminiscent of the juvenile myelomonocytic leukemia (JMML)-like 
myeloproliferative disease (MPD) phenotypes seen following NF1(Nf1) loss of 
heterozygosity (LOH) in the hematopoietic compartment(43,44), and are suggestive of 
TRAPCre recombination of Nf1 in relatively primitive myeloid OC precursors as previously 
reported(29). While the physiological relevance of the Nf1 nullizygosity within the osteoclast 
lineage remains questionable given that NF1 patients suffering from osteopenia/osteoporosis 
typically retain one functional NF1 allele within the hematopoietic compartment, these data 
nonetheless provide critical insight regarding the stage of myeloid/OC differentiation at 
which loss of loss of Nf1 is permissive of OC gain-in-functions.
Nf1-LysM bone marrow mononuclear cells (BMMNCs) exhibit increased colony forming 
unit-macrophage (CFU-M) in methylcellulose culture, enhanced osteoclastogenic capacity 
in response to M-CSF and RANKL, thereby resulting in accelerated osteolytic activity in 
vivo following OVX-mediate pro-resorptive challenge. By contrast, Nf1-Ctsk mice did not 
recapitulate any of these phenotypes in analogous experiments, indicating a critical 
requirement for Nf1 haploinsufficiency at a more primitive stage of myeloid development in 
perpetuating osteolytic activity.
Pu.1 transcriptional activity is indispensable for myelomonocytic and osteoclast 
differentiation, whereby the absence of Pu.1 in mice leads to severe osteopetrosis and 
combined deficiency of both macrophages and OCs secondary to impaired expression of the 
M-CSF receptor, c-Fms (35,45). Intriguingly, however, supraphysiologic levels of Pu.1 
expression do not necessarily correlate with increased myelomoncytic lineage commitment. 
In fact, recent studies suggest that phosphorylation of Pu.1 plays a central role in modulating 
its DNA binding affinity(37,46), and is thereby critical to its ability to activate myeloid 
specific gene programs that promote terminal differentiation(39,40). For instance, although 
human myeloid leukemic cell lines have been shown to overexpress Pu.1(47), the transcript 
levels of Pu.1-dependent myeloid genes, such as CD11b and c-fms, are relatively low by 
comparison(48,49). Carey and colleagues demonstrated that this discrepancy between Pu.1 
expression level and transcriptional activity depends on the phosphorylation status of Pu.
1(37), whereby Pu.1 phosphorylation induced by tetradecanoylphorbol-13 acetate (TPA) led 
to growth arrest in leukemic cells(37). A recent study by Seshire et al. further demonstrated 
that Pu.1 dephosphorylation at serine residues by the leukemia-associated fusion protein 
pro-myelocytic leukemia/retinoic acid receptor alpha (X-RARα) inhibits Pu.1 promoter 
binding and transcription of c-fms among other myelomoncytic genes(40).
In the present study, we demonstrate that the Nf1 tumor suppressor gene modulates nuclear 
levels of phosphorylated Pu.1 in myeloid OC progenitors, whereby M-CSF/RANKL induced 
p21Ras hyperactivation (in the context of Nf1 haploinsufficieny) leads to increased levels of 
phospho-Pu.1 in the nucleus. Re-expression of the human full-length GAP related domain 
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(GRD) of NF1 in primary Nf1+/- c-kit+ hematopoietic cells significantly attenuated the 
phosphorylation of nuclear Pu.1, demonstrating the Ras dependent nature of this process. 
The apparent association between increased phosphorylation of nuclear Pu.1 and enhanced 
osteoclastogenesis in the context of Nf1 haploinsufficiency warrants further investigation in 
future studies.
Collectively, the results of this study suggest that the low bone mass phenotype observed in 
Nf1+/- and Nf1- LysM mice (and possibly the phenotype of osteopenia/osteoporosis in NF1 
patients) may be due to enhanced osteoclast differentiation and recruitment of osteoclast 
progenitors which occurs at a relatively primitive stage of myeloid differentiation, driven by 
Ras mediated hypersensitivity to M-CSF and RANKL. Thus, circumventing the early stage 
recruitment and expansion of the osteoclast progenitor pool by targeting the molecular 
pathways driving this process may represent a rational therapeutic strategy in the treatment 
of NF1-associated osteoporosis. By contrast, bisphosphonates, which have long since been 
the clinical mainstay of in the treatment of osteoporosis, function to induce apoptosis of 
mature, terminally differentiated osteoclasts as they begin to resorb the bone matrix. As they 
accumulate at high concentrations in the bone matrix, bisphosphonates have been associated 
with a number of deleterious effects over time including the accumulation of microfractures 
and osteonecrosis among other complications(50). These pitfalls have led to the advent of 
other novel anti-resorptive therapies such as denosumab(51), which acts at more primitive 
stage of osteoclast development as compared to bisphosphonates by blocking the RANKL-
dependent terminal differentiation of osteoclast progenitor cells.
Evidence regarding the efficacy of bisphosphonates in the treatment of NF1-associated 
osteoporosis are inconclusive. A recent clinical study limited to six patients with quite 
profound osteoporosis did demonstrate a trend toward increased BMD in five out of the six 
patients in the study, although the effect did not reach statistical significance after 23 months 
of treatment(52). By contrast, recent work by Heervä and colleagues has shown that 
osteoclasts derived from human NF1 patients were resistant to bisphosphonate induced 
apoptosis versus healthy controls(53). As such, the application of targeted anti-resorptive 
agents that act at a more primitive stage of osteoclast differentiation may hold therapeutic 
promise in the treatment of NF1 associated osteopenia/osteoporosis and warrants further 
exploration in preclinical studies.
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Key Points
• Nf1 haploinsufficiency in myelomonocytic precursors alters lineage 
commitment, potentiating osteoclast differentiation and lytic activity.
• Nf1 haploinsufficient osteoclast gain-in-functions are associated with Ras-
dependent increases in nuclear phosphorylated Pu.1.
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Figure 1. Nf1 haploinsufficiency in myeloid progenitor cells promotes expansion of the OC 
progenitor population and potentates OC differentiation
(A) The number of colony forming unit monocyte/macrophage (CFU-M) per femur were 
enumerated following 7 days culture in semisolid methycellulose media. **P < 0.01, ***P < 
0.001, Nf1-LysM vs WT. n = 8 mice per genotype. (B) Populations of GMP, myeloid cells, 
and monocytes in the bone marrow were identified by flow cytometry. Fold changes in the 
number of cells per femur are reported. *P < 0.05, Nf1-LysM vs WT. n = 4 mice per 
genotype. (C) Representative photomicrographs show TRACP staining of bone marrow 
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derived osteoclasts cultured in the presence of M-CSF and RANKL for 6 days. (D) The 
number of osteoclasts per high power field (HPF),the number of nuclei per osteoclast, and 
the mean osteoclast size were quantitated as shown. *P < 0.05, **P < 0.01, ***P < 0.001, 
Nf1-LysM vs WT. n = 4 biological replicates per genotype. (E) Representative 
photomicrographs show actin ring formation in bone marrow derived osteoclast cultures at 
50× (top) and 200× (bottom) magnification. Cells were stained with Alexa Fluor® 488 
Phalloidin (green) and Hoechst (blue). (F) Podosome formation was evaluated by 
determining the percent distribution of actin organization into clusters, rings, and belts. *P < 
0.05, Nf1-LysM vs WT. n = 4 biological replicates per genotype. (G) Osteoclasts were 
incubated on dentine slices with representative photomicrographs showing resorptive “pits” 
generated by osteoclast bone lytic activity. Resorptive “pit” area was quantified as shown in 
the bar graph. ***P < 0.001, Nf1-LysM vs WT.
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Figure 2. Conditional Nf1 haploinsufficiency in myeloid progenitor cells potentiates osteolytic 
activity in vivo in response to OVX mediated pro-resorptive challenge
(A) Representative micro-computed tomography (μCT) shows reconstructed femora in 
longitudinal (top) and transverse (bottom) cross-sections 6-weeks post-surgery (OVX vs 
sham-operated controls). (B) The OVX-induced reduction (percentage change) in bone 
mineral density (BMD) of the distal femur was determined by pDEXA measurements 
acquired before and 6-weeks after ovariectomy vs sham surgery. *P < 0.05, OVX Nf1-LysM 
vs OVX WT. WT Sham (n = 5), Nf1-LysM Sham (n = 5), WT OVX (n = 8), Nf1-LysM 
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Sham (n = 10) mice per genotype. (C) Trabecular bone volume fraction (BV/TV) was 
quantified by μCT. WT Sham (n = 6), Nf1-LysM Sham (n = 6), WT OVX (n = 7), Nf1-LysM 
Sham (n = 12) mice per genotype. *P < 0.05, OVX Nf1-LysM vs OVX WT. Trabecular 
microarchitecture parameters including trabecular number (Tb.N) (D), trabecular spacing 
(Tb.Sp) (E), and trabecular thickness (Tb.Th) (F) were quantified by μCT. WT Sham (n = 6), 
Nf1-LysM Sham (n = 6), WT OVX (n = 7), Nf1-LysM Sham (n = 12) mice per genotype. *P 
< 0.05, OVX Nf1-LysM vs OVX WT. (G) Representative photomicrographs of TRACP 
stained distal femora of WT and Nf1-LysM mice 6 weeks following either sham or OVX 
surgery. (H) Osteoclast numbers per mm bone surface (Oc.N/BS) were manually 
enumerated at 100× magnification on TRACP stained sections of the distal femur. WT Sham 
(n = 5), Nf1-LysM Sham (n = 5), WT OVX (n = 3), Nf1-LysM Sham (n = 5) mice per 
genotype. *P < 0.05, OVX Nf1-LysM vs OVX WT.
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Figure 3. Conditional Nf1 heterozygosity in terminally differentiated OCs is not sufficient to 
potentiate bone catabolic activity in ovariectomized Nf1-Ctsk mice
(A) The percentage change in bone mineral density (BMD) 6 weeks status-post OVX vs 
sham surgery was compared between WT and Nf1-Ctsk mice. WT Sham (n = 7), Nf1-Ctsk 
Sham (n = 6), WT OVX (n = 15), Nf1-Ctsk OVX (n = 10) mice per genotype. ns = no 
significant difference. (B) Representative μCT reconstructed femora in longitudinal (top) 
and transverse (bottom) cross-sections for WT versus Nf1-Ctsk mice 6 weeks following 
either sham or OVX surgery. (C) Femoral BV/TV was quantified by μCT as shown and 
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revealed no significant difference between WT and Nf1-Ctsk mice. WT Sham (n = 5), Nf1-
Ctsk Sham (n = 5), WT OVX (n = 12), Nf1-Ctsk OVX (n = 12) mice per genotype. No 
significant differences in trabecular microarchitecture parameters were found when 
comparing connectivity density (Conn.D.) (D), trabecular number (Tb.N) (E), trabecular 
thickness (Tb.Th) (F), trabecular spacing (Tb.Sp) (G), bone surface to bone volume ratio 
(BS/BV) (H), and structure model index (SMI) (I) between WT and Nf1-Ctsk mice 
undergoing OVX surgery. WT Sham (n = 5), Nf1-Ctsk Sham (n = 5), WT OVX (n = 12), 
Nf1-Ctsk OVX (n = 12) mice per genotype.
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Figure 4. Nf1 haploinsufficiency drives p21-Ras dependent phosphorylation of Pu.1 in the 
nucleus of myelomonocytic osteoclast precursors
Primary osteoclast progenitors were isolated from WT and Nf1+/- mice according to the 
same methodology as in previous experiments. (A) Representative photomicrographs of WT 
and Nf1+/- primary OC progenitors stained with FITC-labeled anti-Pu.1 (green) and Hoescht 
(blue). The assay was performed on two independent occasions with similar results. (B) 
Phosphorylated and nonphosphorylated Pu.1 species were detected in OC progenitor nuclear 
lysates by western blot following stimulation with M-CSF and RANKL for 0, 2, 12, and 24 
hours. The expression level of the phosphorylated Pu.1 species was determined by 
densitometry as a ratio to the predominant non-phosphorylated Pu.1 band as in internal 
nuclear loading control. This experiment was repeated three times, with similar results. (C) 
Nuclear protein lysates were prepared from OC progenitors following 12 hours stimulation 
with M-CSF and RANKL. Nuclear lysates were subsequently incubated at 37°C with either 
phosphatase or heat inactivated phosphatase for a duration of 30 minutes prior to 
immunoblotting with anti-Pu.1 antibody. This experiment performed two times, with similar 
results. (D) The human full-length GAP related domain (GRD) of NF1 was re-expressed by 
retroviral transduction of primary c-kit+ hematopoietic cells isolated from the bone marrow 
of WT and Nf1+/- mice. Following puromycin selection, cells were stimulated with M-CSF 
and RANK-L and phosphorylated and non-phosphorylated Pu.1 species were detected in 
nuclear lysates by western blot. Histone H3 was detected as an additional nuclear loading 
control. The ratio of phosphorylated to total Pu.1 was determined by densitometry. This 
experiment was performed twice, with similar results.
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Figure 5. Haploinsufficient loss of Nf1 in myeloid progenitor cells is required to potentiate 
osteolytic activity in a mouse model of NF1 associated osteoporosis
Given that genetic ablation of a single Nf1 allele in terminally differentiated osteoclasts 
alone (Nf1-Ctsk) is insufficient to augment the rate of bone lytic activity, we postulate that 
expansion of the OC precursor pool (Nf1-LysM) and an overall increase in OC numbers are 
the preponderant factors perpetuating excess osteolytic activity in vivo following OVX 
mediated pro-resorptive challenge. These phenotypes are associated with p21-Ras dependent 
hyper-phosphorylation of the myeloid transcription factor Pu.1 in the nucleus of Nf1 
haploinsufficent myelomonocytic OC precursors.
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